Highlights from

AAD 2021

American Academy of Dermatology Virtual Meeting Experience 2021

Virtual 23-25 April 2021

The efficacy and safety of crisaborole in paediatric patients with allergic dermatitis

Summary: Crisaborole is indicated for the topical treatment of mild-to-moderate atopic dermatitis. It is effective and safe in treating patients aged ≥2 years with allergic dermatitis irrespective of atopic comorbidities.

Crisaborole ointment 2% is an anti-inflammatory inhibitor of phosphodiesterase-4. It is available in the US for topical treatment targeting paediatric patients with mild-to-moderate allergic dermatitis (AD) who are at an increased risk of other atopic comorbidities. Two phase III trials (NCT02118766 and NCT02118792) with a randomised, double-blind, vehicle-controlled design were conducted in patients with AD aged ≥2 years. Patients were randomly assigned with a 2:1 ratio to receive crisaborole or a vehicle. The aim was to assess the improvement and time to improvement in Investigator's Static Global Assessment (ISGA) and Severity of Pruritus Scale (SPS) outcomes.

In a post hoc analysis, patients were stratified by history of asthma and/or allergies. The median age was similar across groups (12 years). Significantly higher proportions of crisaborole- than vehicle-treated patients achieved ISGA success, ISGA clear or almost clear, and SPS improvement. Concerning safety, crisaborole had a low frequency of treatment-related adverse events. The most common treatment-related adverse event was application-site pain. One serious adverse event was reported but appeared not related to the treatment.

  1. Lio P, et al. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma. Poster 26304, AAD VMX 2021, 23-25 April 2021.

Top image: © kali9

Article image: imarik

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.